Evaluation of Metal Impurities in Drug Substances

  Рет қаралды 2,916

U.S. Food and Drug Administration

U.S. Food and Drug Administration

Күн бұрын

Пікірлер
Drug Substance Postapproval Changes Guidance: Determination of Impurity Profile Equivalence
23:25
U.S. Food and Drug Administration
Рет қаралды 4,4 М.
Regulatory Considerations for Impurity Qualification: ICH Q3A/Q3C/Q3D, RLD & MDD
28:12
U.S. Food and Drug Administration
Рет қаралды 10 М.
It works #beatbox #tiktok
00:34
BeatboxJCOP
Рет қаралды 41 МЛН
How Strong Is Tape?
00:24
Stokes Twins
Рет қаралды 96 МЛН
Timeline for the Drug Master Review Process
22:08
U.S. Food and Drug Administration
Рет қаралды 4,4 М.
Mutagenic Impurities from a Drug Substance Perspective: Highlights from ICH M7 Q&A Draft Document
12:22
ICH M7(R1) - Chemistry and Manufacturing Control (CMC) Perspective on Hazard Assessment
20:33
U.S. Food and Drug Administration
Рет қаралды 7 М.
Establishing Impurity Acceptance Criteria as Part of Specs for DMFs Based on Clinical Relevance
13:26
Impurity Case Studies: Pharmacology/Toxicology (22of28) Generic Drugs Forum - Apr. 3-4, 2019
25:40
U.S. Food and Drug Administration
Рет қаралды 1,8 М.
FDA Oncology Drug Development Overview - Past to Present
29:20
U.S. Food and Drug Administration
Рет қаралды 4,2 М.
CDER BIMO: Electronic Submission Requirements for New Drug and Biologic Licensing Applications
17:02
FDA Clinical Investigator Training Course (CITC) 2024 - Day One - Session Two
1:42:25
U.S. Food and Drug Administration
Рет қаралды 1,9 М.
FDA Clinical Investigator Training Course (CITC) 2024 - Day Two - Session Two
2:23:52
U.S. Food and Drug Administration
Рет қаралды 654
It works #beatbox #tiktok
00:34
BeatboxJCOP
Рет қаралды 41 МЛН